U.S. Markets closed

Is Minerva Neurosciences Inc (NERV) Undervalued?

Cameron Brookes

Minerva Neurosciences Inc (NASDAQ:NERV), a pharmaceuticals, biotechnology and life sciences company based in United States, Check out our latest analysis for Minerva Neurosciences

What's the opportunity in NERV?

Great news for investors – NERV is still trading at a fairly cheap price. I’ve used the price-to-book ratio in this instance because there’s not enough visibility to forecast its cash flows, and its earnings doesn’t seem to reflect its true value. The stock’s ratio of 2.6x is currently well-below the industry average of 7.4x, meaning that it is trading at a cheaper price relative to its peers. Although, there may be another chance to buy again in the future. This is because NERV’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, NERV’s shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

What kind of growth will NERV generate?

NasdaqGM:NERV Future Profit Sep 13th 17

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares.Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at NERV future expectations. Though in the case of NERV, it is expected to deliver a highly negative earnings growth in the next few years, which doesn’t help build up its investment thesis. It appears that risk of future uncertainty is high, at least in the near term.

What this means for you:

Are you a shareholder? Although NERV is currently undervalued, the adverse prospect of negative growth brings about some degree of risk. I recommend you think about whether you want to increase your portfolio exposure to NERV, or whether diversifying into another stock may be a better move for your total risk and return.

Are you a potential investor? If you’ve been keeping an eye on NERV for a while, but hesitant on making the leap, I recommend you dig deeper into the stock. Given its current undervaluation, now is a great time to make a decision. But keep in mind the risks that come with negative growth prospects in the future.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Minerva Neurosciences. You can find everything you need to know about NERV in the latest infographic research report. If you are no longer interested in Minerva Neurosciences, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.